Biosensors for pathogen detection are designed to bring useful diagnostic information closer to the point where decisions are made. During the COVID-19 emergency, that need sharpened: testing approaches had to address speed and accessibility without losing sight of accuracy. Concepts presented at the 2020 Biosensors for Pandemics conference illustrate the range of engineering strategies under consideration, from paper-based formats to integrated silicon chips and optical sensors. Their shared challenge is to turn a biological target into a dependable result in settings that may lack laboratory equipment or specialist operators.
Why biosensors for pathogen detection matter
Central laboratories can use established molecular and serological testing platforms, but collecting and transporting samples and waiting for analysis can constrain how quickly results inform action. Point-of-care testing aims to move some or all of the testing process closer to the patient or sample. For industrial automation professionals, the underlying design problem will be familiar: integrate sensing, processing and readout into a system that performs reliably under real operating conditions.
A diagnostic device must do more than produce a signal. The result needs to distinguish the target from similar biological material, resist false positives and false negatives, and remain repeatable across tests. Sample preparation, reagent handling, temperature control, signal processing and user interaction can all affect whether a sensing technology is practical outside a laboratory.
Different sensing methods, different trade-offs
The conference program covered several ways to recognize pathogens or their components. Each approach connects a biological interaction to a measurable signal, but the hardware and workflow differ.
- Nucleic acid testing: Molecular methods detect pathogen-specific genetic sequences. One proposed silicon transducer combined a Joule heater, temperature sensor and electrochemical sensor on a chip. It was designed to support either isothermal amplification or temperature-cycled PCR while measuring amplified DNA in real time. The reported work included detection of SARS-CoV-2 complementary DNA and a bacterial DNA target.
- Electrochemical sensing: These biosensors translate recognition events into electrical measurements. Their potential advantages include portable instrumentation and relatively direct readout. Presentations discussed electrochemical detection of pathogen-related targets, including genetic material and proteins.
- Optical and photonic sensing: Nanophotonic, plasmonic and fiber-based systems use interactions between light and a target to generate a signal. A proposed plasmonic design combined localized surface plasmon resonance sensing with photothermal heating to support nucleic acid hybridization and distinguish similar sequences.
- Paper-based and lateral-flow formats: Cellulose-based devices and test strips offer a route to simpler, portable tests. Other work explored porous particles that release indicator molecules when a target displaces an antibody cap, amplifying the detectable signal.
These examples represent different development approaches, not interchangeable solutions. A format suited to genetic analysis may need amplification and temperature management; a strip test may prioritize simple handling and visual or compact readout. The appropriate architecture depends on the target, sample, operating environment and intended use.
From a sensor to a point-of-care system
Miniaturizing the sensing element is only one part of decentralizing diagnostics. A complete point-of-care workflow must connect sample collection to a result that a user can interpret. Some concepts presented at the conference paired biosensors with smartphones or portable electronics. Others aimed to combine amplification and detection in one device, reducing reliance on separate equipment or complex processing steps.
System integration can also support different testing needs. For example, a biosensor may be designed to detect a viral protein for screening, or to identify specific RNA sequences for molecular analysis. Multiplexed formats may examine more than one target, while quantitative readout can provide information beyond a simple positive-or-negative indication. These capabilities require careful engineering of the recognition layer, transducer, assay chemistry and data interpretation.
Manufacturing and supply are further design considerations. The silicon-based transducer described in the proceedings used wet-etching and other processes intended to avoid advanced semiconductor-fabrication facilities. Paper-based devices, meanwhile, draw interest because cellulose is abundant and can be formed into different structures. Such approaches reflect a broader objective: develop platforms that can be produced and deployed without making access to specialized infrastructure a prerequisite.
Validation is as important as speed
Rapid results are valuable only when test performance is understood. Evaluation should consider sensitivity and specificity alongside repeatability, robustness and the likelihood of misleading results. The conference material also emphasized the importance of assessing rapid tests in relation to clinical practice and the requirements of the intended health system.
Performance claims must be interpreted in context. A sensor’s result in a controlled experiment does not, by itself, establish suitability for routine deployment. Sample type, preparation, target concentration, operator steps and comparison with established methods all influence how a test performs in use. The intended application should therefore guide both engineering requirements and validation.
Practical implications for system designers
For engineers and technical decision-makers evaluating biosensing technologies, the central question is not simply which transducer is most sensitive. It is whether the complete test can deliver a reliable, usable result within the constraints of its deployment environment. Key considerations include:
- Which biological target is being measured: genetic material, protein or another biomarker?
- What sample preparation and amplification steps are required?
- How are temperature, timing and reagent handling controlled?
- Can the readout be interpreted consistently by the intended user?
- What validation is needed for the specific sample and use case?
- Can the device be manufactured and supplied in the locations where it is needed?
Conclusion
The biosensor approaches explored for pandemic response show how biological recognition, microfabrication, nanomaterials, electronics and optical systems can be combined for faster, more decentralized testing. The practical opportunity lies in treating the device as a complete diagnostic workflow—not just a sensitive sensor. For system integrators and decision-makers, successful adoption will depend on matching the sensing method to the target and operating context, then demonstrating that the full test is accurate, repeatable and straightforward to use.